Oramed Pharmaceuticals (ORMP) Interest Expenses (2010 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Interest Expenses came in at $158000.0 in Q1 2026, up 1480.0% YoY from $10000.0 in Q1 2025, and up 28.46% on a QoQ basis from $123000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Interest Expenses (2010 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 17 years of Interest Expenses data on file, last reported at $158000.0 in Q1 2026.
- Quarterly Interest Expenses rose 1480.0% year-over-year to $158000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $158000.0 (up 1480.0% YoY) and the FY2025 annual result came in at $238000.0, down 99.34% from the prior year.
- Interest Expenses grew to $158000.0 in Q1 2026, from $123000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $2.9 million in Q4 2023 to a low of -$2.1 million in Q4 2024.
- A 5-year average of $433294.1 and a median of $261000.0 in 2024 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 5820.0% in 2024, down 169.6% in 2024.
- Tracing ORMP's Interest Expenses over 5 years: stood at $87000.0 in 2022, then surged by 3287.36% to $2.9 million in 2023, then plunged by 169.6% to -$2.1 million in 2024, then soared by 106.0% to $123000.0 in 2025, then gained by 28.46% to $158000.0 in 2026.
- The last three Interest Expenses figures came in at $158000.0 (Q1 2026), $123000.0 (Q4 2025), and $134000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 838,000.00 |
| Jun 30, 2026 | 838,000.00 |
| Mar 31, 2026 | 158,000.00 |
| Mar 31, 2026 | 158,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Sep 30, 2025 | 134,000.00 |
| Jun 30, 2025 | 134,000.00 |
| Jun 30, 2025 | 134,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | -2.05 Mn |
| Dec 31, 2024 | -2.05 Mn |
| Sep 30, 2024 | 445,000.00 |
| Sep 30, 2024 | 445,000.00 |
| Jun 30, 2024 | 261,000.00 |
| Jun 30, 2024 | 261,000.00 |
| Mar 31, 2024 | 592,000.00 |
| Mar 31, 2024 | 592,000.00 |